Status:

COMPLETED

Ph II Early BC Pre-Surgical Biologic Study

Lead Sponsor:

AstraZeneca

Collaborating Sponsors:

Cancer International Research Group (CIRG)

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

A pre-surgery study to assess changes that occur in human breast cancer material and normal skin after a short course of treatment with Iressa.

Eligibility Criteria

Inclusion

  • Invasive breast cancer, Aged 18 years or older, Not more than 28 days from initial diagnosis

Exclusion

  • Pregnant or lactating patients, Prior or current radiotherapy for breast cancer, Known allergy reaction to Iressa

Key Trial Info

Start Date :

July 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2005

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT00637026

Start Date

July 1 2003

End Date

February 1 2005

Last Update

April 23 2009

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Ph II Early BC Pre-Surgical Biologic Study | DecenTrialz